



01645/2/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Lee et al.) ATTORNEY DOCKET NO.: 01645/2/US
SERIAL NO.: 10/626,275) GROUP ART UNIT: Unknown
FILED: July 24, 2003) EXAMINER: Unknown
TITLE: PRAMIPEXOLE ONCE-DAILY DOSAGE FORM
DATE: September 16, 2003

CERTIFICATE OF MAILING

I hereby certify that this IDS and recited enclosures are being deposited with the U.S. Postal Service as First Class Mail in a package addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on September 16, 2003.

Insan B. Sawlik

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

INFORMATION DISCLOSURE STATEMENT

This Information Disclosure Statement (IDS) is filed in accordance with the duty of disclosure under 37 C.F.R. § 1.56 and §§ 1.97-1.98, as supplemented by MPEP § 609. Presentation of documents listed on enclosed Form PTO-1449 is not an admission that any listed document is prior art under the Patent Statutes and the right is reserved to antedate any material described in the listed documents by a showing under 37 C.F.R. § 1.131 or otherwise.

This IDS is filed under the provisions of 37 C.F.R. § 1.97(b) and no fee is believed payable in respect of this IDS. However, if it is determined that a fee is payable, please charge such fee to Deposit Account No. 19-1025.

Respectfully submitted,




James C. Forbes
Agent for Applicant
Registration No. 39,457
Tel. 847-581-6090

Address correspondence to:

Pharmacia Corporation
Patent Department
P.O. Box 1027
St Louis, MO 63006

Enclosures:

Form PTO-1449
Cited art
Post Card

Form PTO-1449 (Rev. 3-03)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket Number 01645/2/US		Application Number 10/626,275	
 INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				First Named Inventor Ernest J. Lee			
				Filing Date July 24, 2003		Group Art Unit Unknown	
U.S. PATENT DOCUMENTS							
Examiner Initial*		Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Class	Subclass	Filing Date If Appropriate
		US 5,458,887	Oct 17, 1995	Chen et al.	424	464	
		US 5,656,296	Aug 12, 1997	Khan et al.	424	473	
		US 6,197,339	Mar 6, 2001	Ju	424	468	
FOREIGN PATENT DOCUMENTS							
Examiner Initial*		Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Class	Subclass	Translation Yes No
		EP 0 933 079	Aug 04, 1999	Cerestar Holding BV	A61K	9/20	
OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)							
		Biglan & Holloway, (2002), <i>Expert Opinion on Pharmacotherapy</i> , 3(2), pp. 197-210					
		Colosimo & De Michele, (1999), <i>European Journal of Neurology</i> , 6(1), pp. 1-21					
		Dooley & Markham, (1998), <i>Drugs & Aging</i> , 12(6), pp. 495-514					
		Hiestand & Smith, (1984), <i>Powder Technology</i> , 38, pp. 145-159					
		Hiestand & Smith, (1991), <i>International Journal of Pharmaceutics</i> , 67, pp. 231-246					
		Hubble et al., (1995), <i>Clinical Neuropharmacology</i> , 18(4), pp. 338-347					
		Physicians' Desk Reference, 57 ed. (2003), pp. 2768-2772					
		USP 24 th ed., (2000), pp. 1941-1943					
		Wright et al. (1997), <i>Journal of Clinical Pharmacology</i> , 37, pp. 520-525					
Examiner				Date Considered			
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							